Grant Funding Opportunities: 6/13/2014
Weekly Grant Funding Opportunities
Please feel free to send special funding search requests any time (susan_craft@ncbiotech.org). Grant funding requests are included our regular research and include a fee of $100/hour. Also, let us know if any of your partners have submitted grant applications to funding announcements posted in the weekly grant alert emails. We would love to hear of their successes!
Visit NCBiotech’s Funding Gateway page to get more information on funding announcements, links to opportunity search databases and grant development tips.
Upcoming Deadlines
Deadline: Rolling
Agency: Leukemia & Lymphoma Society
Program: Biotechnology Accelerator Division
Description: The Biotechnology Accelerator Division identifies companies developing novel anti-cancer therapies and invests in specific projects to assist in gaining proof-of-concept findings that can demonstrate safety and therapeutic efficacy for blood cancer patients. Your company must have potential or active projects related to preventing, diagnosing or treating blood cancers. The Biotechnology Accelerator Division is more likely to fund projects that will potentially net key results that will enable a company to partner or raise additional funding to complete the testing, registration and marketing of new therapies or diagnostics for a blood cancer indication.
Award Amount: Varies
Website: www.lls.org/researchershealthcareprofessionals/drugdevelopment/therapyacceleration/
Eligibility: Companies that have potential or active projects related to preventing, diagnosing or treating blood cancers. The project must be at a late preclinical or an early clinical development stage. The compounds, biologics or diagnostic devices in development must have a high, near-term probability of providing benefits to patients. Companies must have additional funding sources to complement the LLS funding.
Deadline: 6/21/2014
Agency: Food & Drug Administration
Program: Effect of Therapeutic Class on Generic Drug Substitutions
Description: The purpose of this study is to rank order generic drugs based on therapeutic class with low generic substitution/acceptance rate and analyze factors affecting the generic substitution in each therapeutic class. The outcome of this study will help identify research needs and align FDA’s regulatory science efforts to monitor and ensure successful generic substitution and thereby assure the public about generic drug safety and efficacy.
Award Amount: $400,000
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=254473
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others
New Opportunities
Deadline: 7/9/2014
Agency: Department of Defense
Program: DoD Prostate Cancer Exploration-Hypothesis Development Award
Description: The PCRP Exploration – Hypothesis Development Award mechanism was first offered in FY03. Since then, 2,184 Exploration – Hypothesis Development Award applications have been received, and 237 have been recommended for funding. The Exploration – Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. The PCRP seeks applications from investigators from a wide spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. In addition, applicants are expected to address at least one of the PCRP focus areas and one of the PCRP overarching challenges. Research involving human subjects is encouraged under this funding opportunity but is restricted to studies without clinical trials.
Award Amount: $2,400,000
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=256291
Eligibility: Unrestricted
Deadline: 7/11/2014
Agency: National Institutes of Health
Program: NEI Administrative Supplements to Small Business Innovative Research (SBIR) Grants for the Procurement of Expertise in the Federal Regulatory Approval Process for New Drugs and/or Devices (Admin Supp)
Description: Only NEI-funded R43/R44 SBIR grantees are eligible to apply. This announcement is for supplements to existing projects. To be eligible, the parent award must be active and the research proposed in the supplement must be accomplished within the competitive segment. The proposed supplement must be to provide for an increase in costs due to unforeseen circumstances. All additional costs must be within the scope of the peer reviewed and approved project. IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project.
Award Amount: Varies
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=254610
Eligibility: Small businesses
Deadline: 7/24/2014
Agency: Department of Defense
Program: DoD Tuberous Sclerosis Complex Pilot Clinical Trial Award
Description: The TSCRP Pilot Clinical Trial Award mechanism was offered for the first time in FY13. Since then, four Pilot Clinical Trial Award applications have been received and one has been recommended for funding. The TSCRP Pilot Clinical Trial Award mechanism supports exploratory studies involving limited human exposure that produce diagnostic or therapeutic information (e.g., screening studies, microdose studies), toxicity studies of an intervention, and studies to determine the mechanism of action and side effects of an intervention. These studies should be aimed at obtaining preliminary data leading to the development of interventions, as well as clinical biomarkers, and endpoints, with the potential to improve TSC outcomes. Examples of studies include but are not limited to the following:• Identification of an appropriate population.• Identification of the dosage, duration, and/or delivery strategy of an intervention.• Evaluation of the feasibility of the intervention in TSC.• Evaluation of efficacy and safety. If the clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required and must be submitted to the FDA prior to the application submission deadline. If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA prior to the application submission deadline, or that the device is exempt from an IDE, is required.
Award Amount: $ 640,000
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=256020
Eligibility: Unrestricted
Deadline: 7/29/2014
Agency: National Institutes of Health
Program: HIV Vaccine Research and Design (HIVRAD) Program
Description: The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address important scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive modeling of vaccine concepts in non-human primates may be included.
Award Amount: $5,000,000
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=254689
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others